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Abstract  
Background 
Rotavirus is a major contributor to child mortality. Rotavirus vaccine impact on diarrhoea 
mortality has been estimated in middle- but not low-income settings, where mortality is high 
and vaccine effectiveness against hospitalisation is lower. Empirical population-based 
mortality studies have not been conducted in any setting. Malawi introduced monovalent 
rotavirus vaccine (RV1) in October 2012.  
 
Methods 
We evaluated RV1 impact and effectiveness (VE) against diarrhoea-associated infant (10-51 
weeks) mortality using a population-based cohort study of infants born 1st January 2012 to 1st 
June 2015 in Mchinji, Central Malawi. Individual vaccination status was extracted from 
caregiver-held records or report at home visits at four months and one year of age. Survival to 
one year was confirmed at home visit, or cause of death ascertained by verbal autopsy. Impact 
(one minus mortality rate ratio following-vs-before vaccine introduction) was evaluated using 
Poisson regression. Among vaccine-eligible infants (born from 17th September 2012), VE (one 
minus hazard ratio) was evaluated using Cox regression.  
  
Results 
We recruited 48,672 live births in Mchinji, among whom 38,518 were vaccine-eligible and 
37,570 survived to age ten weeks. VE analysis included 29,085 infants, of whom 108 had 
diarrhoea-associated death before one year of age. Diarrhoea-associated mortality declined 
31% (95% CI: 1, 52; P=0.04) following RV1 introduction. VE against diarrhoea-mortality was 
34% (95% CI: -28, 66, P=0.22).  
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Conclusions 
RV1 substantially reduced diarrhoea deaths among infants in this rural, sub-Saharan African 
setting. These data add considerable weight to the evidence demonstrating the impact of 
rotavirus vaccine programmes. 
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Research in context 
Evidence before this study 
Rotavirus vaccine has been introduced in many high mortality, low income Gavi-supported 
countries, but mortality impact or effectiveness estimates are lacking from these settings. We 
searched PubMed using the term ((rotavirus vaccine[Title/Abstract] AND 
(mortality[Title/Abstract] OR death[Title/Abstract])) NOT "review"[Publication Type] 
NOT cost-effectiveness[Title]). Title/abstract review of 185 arising citations performed 
independently by the two first authors excluded review articles and secondary publication of 
data.  Thirteen studies, all from middle-income countries, were identified. Botswana and 
Panama reported hospitalised case fatality reductions of 48% and 45%, respectively, but did 
not report on population mortality.  All other studies (Bolivia 1, Brazil 5, Mexico 3, 
combined South American countries 2) used time series analyses of national administrative 
datasets to estimate mortality reductions following rotavirus vaccine introduction. These 
studies report infant diarrhoeal-mortality reductions of between 21% and 41%, with higher 
estimates noted within rotavirus season. No mortality impact data were identified from low-
income countries. Prospective, population based studies evaluating rotavirus vaccine impact 
on mortality have not been published from any country. In southern Malawi, RV1 
introduction was associated with 43% reduction in laboratory proven rotavirus infant 
hospitalisation, with vaccine effectiveness of 64% and was highly cost-effective. 
What this study adds 
This large population based birth cohort study is the first to report rotavirus vaccine 
associated infant mortality reductions from a low-income country using the WHO 
recommended EPI schedule of 6 and 10 weeks, and demonstrates a relationship between 
coverage and mortality impact gained. In addition, this study demonstrates a possible added 
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benefit on diarrhoeal mortality of vaccine introduction in the context of enhanced water, 
hygiene and sanitation improvements. 
Implications of all the available evidence 
In addition to morbidity impact and high cost-effectiveness, countries with national or 
localised areas of high diarrhoeal mortality should consider introducing rotavirus vaccines 
for their survival benefits. Vaccine implementation combined with improvement in water 
and sanitation may provide maximum impact. 
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Introduction 1 
Diarrhoea causes 17% of post-neonatal infant deaths globally.1 Despite impressive survival 2 
gains from improved sanitation and case management, in 2013 rotavirus, the greatest 3 
contributor to this mortality still caused 215,000 child deaths, 121,000 of these in Africa.2  4 
Subsequently, with support from Gavi the Vaccine Alliance, many African countries with the 5 
highest mortality burdens have introduced live attenuated rotavirus vaccines.3  6 
 7 
Vaccine impact (population reductions in disease burden following vaccine introduction) and 8 
vaccine effectiveness (individual protection afforded by vaccination, henceforth VE) on 9 
hospitalized rotavirus gastroenteritis has been shown in high, middle and low-income 10 
countries.4-7 Vaccine efficacy against laboratory proven rotavirus in clinical trials is lower in 11 
low-income, high-mortality countries than in high income, low-mortality countries. Therefore 12 
to support widespread implementation, evidence of rotavirus vaccine impact on population-13 
level mortality and real-world effectiveness on individual risk of death is crucially important. 14 
Vaccine impact on mortality has been demonstrated through analysis of administrative datasets 15 
from middle-income countries in Central and South America.8-10 However, no direct mortality 16 
benefit of rotavirus vaccination has been documented at population level from a low-income, 17 
high-burden setting. 18 
 19 
Malawi, a low-income country in Sub-Saharan Africa, with year-round rotavirus transmission, 20 
has made sustained efforts to reduce child mortality and in 2015 had reached the Millennium 21 
Development Goal target of reducing child mortality by two thirds from 1990 levels. In Malawi 22 
health centres and community based Health Surveillance Assistants (the community healthcare 23 
workers/vaccinators in Malawi, henceforth HSA) routinely provide oral rehydration solution 24 
and zinc for diarrhoeal disease, and these are widely available. 13-valent Pneumococcal 25 
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Conjugate Vaccine was introduced into Malawi’s National Immunisation Programme with 26 
three doses given at 6, 10, and 14 weeks of age on 12th November 2011. Monovalent rotavirus 27 
vaccine (Rotarix™, RV1) at the WHO recommended schedule of 6 and 10 weeks, was 28 
introduced on 29th October 2012, without catch-up. We have demonstrated RV1 efficacy 29 
(49%, 95% CI: 19, 68), effectiveness (64%, 95% CI: 24, 83) and impact (43%, 95% CI: 18, 30 
61) on severe laboratory confirmed rotavirus gastroenteritis in Malawian infants, and have 31 
shown that RV1 is highly cost-effective in this setting.6, 7, 11, 12  32 
 33 
We aimed to evaluate population-level impact and individual-level effectiveness of RV1 34 
against diarrhoea-associated mortality using a large prospective population-based birth cohort 35 
in a rural population in Mchinji district, Central Malawi (Site 1). In order to validate our 36 
estimate of RV1 programme impact, we also undertook concurrent impact evaluation in a 37 
smaller separate population in Chilumba, Northern Malawi (Site 2, Appendix 1 Fig. 1) .13 We 38 
present the studies at each site in turn. 39 
  40 
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Methods  41 
Prior to study commencement, extensive community engagement and consultation activities 42 
were undertaken with Traditional Authorities, village chiefs, health committees, women’s 43 
groups, District and Environmental Health Officers, health centre managers and HSAs to 44 
ensure the study was welcome in communities and households.  45 
 46 
Site 1: Mchinji district - prospective population-based birth cohort 47 
 48 
Setting  49 
Site 1 population was 456,516 persons in the 2008 national census, with a crude birth rate of 50 
32 per 1000 population and post-neonatal infant mortality rate of 28 per 1000 live births in 51 
2015.14, 15  The district is rural and borders Zambia and Mozambique. Its sparsely populated 52 
villages and agricultural estates are interspersed with semi-urban trading-centres. The economy 53 
is based on subsistence maize farming. Electricity is available in 3.3% of households. 15 This 54 
district was the location of a previous cluster randomised trial, with strong community support 55 
for research. It had the requisite infrastructure to expand to district-wide mortality surveillance, 56 
and allowed us to undertake a large-scale population-based birth cohort study. 57 
 58 
Data collection and validation 59 
We conducted a baseline district-wide census in March 2012 to obtain household membership 60 
and create community-held household registers. We established prospective household 61 
surveillance in 1,832 census-enumerated villages within all 354 HSA clusters by a cadre of 62 
1059 village-based key informants (KIs), who were selected by village health committees. KIs 63 
conducted continuous household surveillance and maintained updated paper-based household 64 
registers for about 100 households each, recording all pregnancies, birth outcomes and deaths 65 
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of children under-5 and of women of childbearing age. KIs were supervised by and reported 66 
data monthly to 50 enumerators, who electronically scanned the updated registers.  67 
Enumerators conducted home visits of all liveborn infants at four and 12 months of age to 68 
record vaccination status and confirm survival. The system was supervised by eight monitoring 69 
and evaluation officers (MEOs). Deaths reported by informants were verified and cause of 70 
death determined by verbal autopsy (VA) conducted as culturally appropriate at least two 71 
weeks after death, by specially trained MEOs using the WHO 2012 VA instrument captured 72 
electronically at the household using Open Data Kit software (https://opendatakit.org/ ).16 We 73 
have published a detailed description of this surveillance system.13  74 
 75 
Vaccine status was obtained from a scanned image of government issued caregiver-held 76 
vaccine record (health passport) and caregiver report (at household visits by enumerators at 77 
four and 12 months of age or by MEOs following death). Caregivers were asked directly about 78 
receipt and date of each dose of every vaccine to which the child was age-eligible under the 79 
National Immunisation Programme. Vaccine status was cross checked against vaccination 80 
centre registers in a sub-set of records for quality assurance. Final vaccine status was 81 
determined per criteria outlined in Web appendix 4. Additionally, throughout recruitment, 82 
interviews with mothers following infant vaccination at randomly allocated clinics compared 83 
reported vs recorded vaccine receipt. Throughout recruitment, enumerators collected socio-84 
demographic data on maternal vital and marital status, educational level obtained, and on 85 
house, water source and sanitation quality. Quality controls were embedded in the database 86 
which automatically triggered field checks in case of error or anomalous runs of data (e.g. no 87 
births in a catchment for three months). MEOs met monthly to review data quality and 88 
timeliness and address field challenges.  89 
 90 
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Cohort definitions 91 
Infants surviving at least ten weeks of age who were born between 1st January 2012 and 16th 92 
September 2012 constituted the pre-vaccination cohort. Those born between 17th September 93 
2012 (i.e. eligible for 1st dose RV1 on the date of vaccine introduction) and 1st June 2015 94 
constituted the vaccine-age eligible cohort. Impact analysis compared both cohorts, while 95 
analysis of individual survival for VE was conducted in the vaccine-eligible cohort only. Live 96 
births were followed to one year of age or death or were excluded if they migrated. One year 97 
follow-up concluded 1st June 2016. Diarrhoea-associated death was defined as any deceased 98 
child whose caregiver reported non-bloody diarrhoea in the illness preceding death upon direct 99 
closed questioning at VA.  100 
 101 
Analysis 102 
Vaccine programme impact was derived as one minus diarrhoea-associated-mortality rate ratio 103 
in the vaccine-eligible cohort vs pre-vaccine-introduction cohort following and prior to vaccine 104 
introduction using Poisson regression adjusted for socio-demographic covariates (Table 1).  105 
The relative brevity of the pre-vaccine-introduction period at Site 1 precluded adjustment by 106 
year. We also performed analysis restricted to January-June, months with known high rotavirus 107 
prevalence in Blantyre, Malawi.17 To examine the relationship between population vaccine 108 
coverage and mortality, we Poisson regressed the mortality rate against two-dose vaccine 109 
coverage (proportion of 2-dose-eligible infants in the population who actually received both 110 
doses) over time and by HSA cluster.18 For HSA cluster analysis of mortality vs vaccine 111 
coverage we also adjusted for cluster-specific means of household-level socio-demographic 112 
covariates, but had no data on communal assets such as state of roads or public infrastructure. 113 
Plotting of mortality rates over time used locally weighted moving average smoothing (Fig. 2).  114 
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Two (vs zero) dose VE was calculated as (one minus hazard ratio) using Cox proportional 115 
hazards modelling of diarrhoea-associated death occurring at 10-51 completed weeks of life. 116 
Because children may die from causes other than diarrhoea, we also performed competing risk 117 
survival analysis. Multivariable modelling was used to adjust for socio-demographic covariates 118 
using complete-case analysis (Table 1). We have previously published the primary analysis 119 
plan and justification.19 In case of violation of the proportional hazards assumption and to better 120 
understand how VE may be related to age, we conducted fully parametric survival analysis 121 
using Royston-Parmar modelling (Fig. 3, panels b, c & d).20 We examined whether cluster-122 
level determinants influence individual level mortality hazard using random effects 123 
hierarchical models. 124 
 125 
Sample size 126 
In our sentinel hospital in Blantyre, rotavirus prevalence in severe gastroenteritis is 35% overall 127 
and 51% in peak periods; we therefore presumed rotavirus prevalence of 45% in diarrhoea-128 
associated deaths.6, 21 Given our published VE against hospitalised rotavirus gastroenteritis in 129 
Malawian infants is 64%, we assumed VE against very severe rotavirus gastroenteritis (leading 130 
to death) would be higher at 70 to 80%. Applying a presumed 76% reduction to the 45% of 131 
deaths presumed attributable to rotavirus, gave a VE of 34% against all-cause diarrhoea-132 
associated death. Based on our established surveillance prior to RV1 introduction, we expected 133 
1500 births per month and post-neonatal infant mortality rate (PNIMR) of 18 per 1000 live 134 
births, of which six were diarrhoea-associated. We assumed 60% mean vaccine coverage over 135 
the recruitment period. Inflating for 12% loss to follow-up, we required 36,293 10-week 136 
survivors to obtain 80% power to detect VE≥34%.  137 
 138 
Site 2: Validation of Impact Estimate  139 
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A Demographic Surveillance Site (DSS) covering 35,000 individuals has operated in the 140 
remote lakeside region of Chilumba, Northern Malawi since 2002.22 Crude birth rate was 30.8 141 
in 2015, post-neonatal infant mortality 15 per 1,000 live births and electricity available in 8.7% 142 
of households.15 This longstanding DSS provided robust data on historical mortality rates in 143 
infants prior to vaccine introduction from 2004, and was therefore considered useful for 144 
independent impact evaluation. Individual survival analysis was precluded by the small total 145 
population. In this site, births, deaths and migrations were reported monthly by village 146 
informants and validated in a rolling annual re-census as previously described.22 Verbal 147 
autopsies were conducted at home visit as locally culturally appropriate at least two weeks after 148 
death. Socio-demographic covariates and vaccine status were collected on age-eligible children 149 
at the time of census visit with vaccination date transcribed from caregiver-held record or 150 
caregiver report. Monthly population-based diarrhoea-associated mortality rate among ten-51 151 
week old infants was Poisson regressed against vaccine coverage, adjusting for year to account 152 
for long-term trend (Fig. 2 panel b). 23 Unbeknownst to us at planning phase, the Red Cross 153 
implemented rapid, widespread and sustained water and sanitation interventions (WASH) 154 
across the Site 2 DSS area alongside national vaccine introduction.24 Site 2 could therefore no 155 
longer serve its intended validation function, but afforded an unplanned opportunity to evaluate 156 
the combined impact of vaccination with WASH as a post-hoc analysis. 157 
 158 
Ethics 159 
Malawi’s National Health Sciences Research Committee (#837) and the London School of 160 
Hygiene and Tropical Medicine (#6047) provided ethical approval. 161 
 162 
Results  163 
 164 
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Site 1  165 
Cohort Description 166 
We registered 48,672 live births. Of these, the pre-vaccination cohort (born between 1st January 167 
2012 and 16th September 2012) comprised 10,154 infants, among whom 7,818 survived 10 168 
weeks and were included in analysis (Appendix 1 Fig. 2). The vaccine-eligible cohort (born 169 
between 17th September 2012 to 1st June 2015) numbered 38,518. Among these 37,570 170 
survived to ten weeks, and 29,085 were included in analysis, of whom 108 died with diarrhoea 171 
before one year of age (Fig. 1). Among the vaccine-eligible cohort mean age at diarrhoea-172 
associated death was 34 weeks, and 27 weeks for non-diarrhoea associated death (t-test 173 
P<0·001). Two-dose RV1 coverage was 90·6% overall; 90·8% in survivors and 84·3% in 174 
deceased infants. Health passports were seen in 90% of infants overall, but ascertainment 175 
differed by survivorship; 91% in survivors and 40% among the deceased. Socio-demographic 176 
factors were similar among survivors and deceased infants, except for maternal marital status 177 
or maternal death (Table 1). Compared with baseline assumptions (see Sample Size), in the pre-178 
RV1 period, monthly births were 1,112, PNIMR 18·8, diarrhoea-associated mortality 5·6, and 179 
loss to follow-up 18%. Post-hoc exploratory analysis found that infants lost to follow-up had 180 
younger (mean age: 25 vs. 27 years) but more educated mothers (15% vs. 12% secondary 181 
education) who were more likely to be unmarried (86% versus 89% married) and have slightly 182 
better housing quality (11% vs 9% best quality). 183 
 184 
Mortality Impact 185 
Prior to vaccine introduction, 44 of 7,818 surviving ten-week olds died with diarrhoea before 186 
one year of age (mortality rate [MR] 5·6 per 1000 live births) (Fig. 2 panel a). Among the 187 
vaccine age-eligible cohort, 108 of 29,085 surviving ten-week olds died of diarrhoea before 188 
one year of age (MR 3·7). Unadjusted and socio-demographically adjusted Poisson regression 189 
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estimated vaccine impact on diarrhoea-associated mortality was 34% (95% CI: 6, 53; P=0.03; 190 
N=36,900) and 31% (95% CI: 1, 52; P=0.04N=36,770), respectively. For equivalent January-191 
June periods assumed to represent peak rotavirus prevalence, in the post-introduction years 192 
2013 to 2015 the diarrhoea-associated mortality per 1000 was 3·7, 2·1 and 2·6 and respective 193 
impact was 44% (95% CI: -3, 70; P=0.06), 67% (95% CI: 31, 85; P=0.003) and 61% (95% CI: 194 
19, 81; P=0.01) (Table 2). All-cause mortality rate reduction post RV1 introduction was 25% 195 
(95% CI: 8, 39; P=0.008).  196 
 197 
Mortality vs. vaccine coverage 198 
Among 354 HSA clusters of approximately 1,300 persons each,18 mean post-neonatal infant 199 
mortality per 1000 was 12·3 (range 0, 76·9) and diarrhoea-associated mortality was 3·6 (range 200 
0, 64·5). Two-dose vaccine coverage ranged from 63·6 to 100% across clusters; each 201 
percentage point greater vaccine coverage was associated with a 1·6% (95% CI: 0·8%, 2·5%) 202 
lower diarrhoea-associated mortality rate (Web extra Figure 3). Adjusting for socio-203 
demographic covariates the reduction was 1.1% (95% CI: 0.9%, 1.3%) 204 
 205 
Vaccine effectiveness 206 
Among 26,352 fully RV1 vaccinated infants 91 (0·4%) died, while among 1,789 unvaccinated 207 
infants ten (0·6%) died (Fig. 3, panel a). Unadjusted and adjusted Cox modelling respectively 208 
gave 2-dose VE against diarrhoea-associated mortality of 39% (95% CI: -16, 68) and 34% 209 
(95% CI: -28, 66) (Table 1). Adjusting for HSA catchment area using a random effects 210 
hierarchical model gave a VE of 36% (95% CI: -24, 67; likelihood ratio [LR] test p<0·001).  211 
Analysis of Schöenfeld residuals showed no evidence of violation of the proportional hazards 212 
assumption (p = 0·23). Competing risks regression gave a VE of 28% (95% CI: -43, 67). 213 
Royston-Parmar model derived VE estimates showed high VE in early infancy which declined 214 
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after 6 months of age (Fig. 3 panel c). Further sensitivity analyses and effectiveness against all-215 
cause mortality are presented in Appendix 2.  216 
 217 
 218 
Site 2  219 
Between 1 January 2004 and 1 June 2015, 15,394 live births were recorded. Of these 3,531 220 
were eligible for RV1 among whom 3,433 survived to 10 weeks. Follow-up was completed on 221 
1 June 2016 for 3,249 infants, of whom 3,235 survived to 1 year. Of the 14 deceased infants, 222 
three died with diarrhoea.  223 
 224 
All-cause and diarrhoea-associated deaths were declining since 2006, but were substantially 225 
lower since RV1 introduction and the Red Cross WASH interventions (Fig. 2 panel b). 226 
Adjusting for year to account for the longer-term trend, Poisson regression of raw monthly 227 
diarrhoea-associated mortality before and after these interventions gives mortality-rate 228 
reduction of 46% (95% CI: 26, 60) P<0.001.  229 
 230 
  231 
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Discussion  232 
In this large population-based birth cohort study, national introduction of RV1 was associated 233 
with a 31% reduction in diarrhoea-associated mortality in infants surviving to at least ten weeks 234 
of age, and the degree of impact was strongly associated with vaccine coverage. Point estimate 235 
for individual protection from diarrhoea-associated mortality was 34%, though too few cases 236 
of diarrhoeal death occurred following introduction to achieve sufficiently precise confidence 237 
bounds. In the context of published RV1 impact (43%) and effectiveness (64%) estimates 238 
against laboratory-proven rotavirus hospitalization from Blantyre in Southern Malawi, our 239 
estimates of impact (31%) and effectiveness (34%) against aetiologically non-specific 240 
diarrhoea-associated death have prima facie validity.6 The higher effectiveness observed in 241 
months known to have high rotavirus prevalence (January to June) and the association between 242 
vaccine coverage and impact further attest to causal plausibility. These data from a low-income, 243 
high-burden setting therefore provide compelling evidence of RV1 impact on diarrhoea-244 
associated infant mortality. 245 
 246 
The estimates of mortality impact in Site 1 are similar to those found in previous analyses of 247 
administrative datasets in middle-income countries.8-10, 25 RV1 introduction in Mexico and 248 
Brazil, for example, was associated with diarrhoeal-mortality rate reduction in infants of 41% 249 
and 21% respectively.8, 9 25 Botswana, a sub-Saharan middle-income country reported a 48% 250 
(95% CI: 11, 69) reduction in hospitalised case fatality during the rotavirus season and similar 251 
findings have been reported from Panama; though neither study measured population 252 
mortality.26, 27 The comparable levels of protection found in our low-income Sub-Saharan 253 
African setting is encouraging, as children from this region account for more than half of global 254 
diarrhoea deaths, and with 31 African countries thus far introducing rotavirus vaccine the 255 
absolute impact on mortality is likely to be substantial. 2, 3  256 
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 257 
The cohort design allowed us to estimate hazard and VE by age, a metric that has been 258 
approximated in case-control studies.28 The observed hazard by age mimics the age at 259 
laboratory-confirmed rotavirus hospitalization seen in our sentinel surveillance site in Blantyre 260 
(Fig. 2 panel b). The apparent decline in VE with age is unlikely to be due to individual 261 
immunological waning before 12 months, but could be explained by changes in the force of 262 
infection through indirect effects.12  If rotavirus prevalence is declining (Table 2), the hazard 263 
for unvaccinated infants declines, so the measurable protection afforded by vaccine direct 264 
effects is thereby reduced.  Survivorship bias may also contribute to lower VE estimates in 265 
older infants, since survivors who happen to receive vaccination late do not contribute their 266 
pre-vaccination survival time to the unvaccinated cohort and survivors are implicitly more 267 
robust. 268 
 269 
The greater individual level VE against all-cause mortality than against diarrhoea-associated 270 
mortality (Web Extra Table 2·5) in Site 1 is explained by confounding. Infants who did not 271 
receive RV1 had a greater likelihood of not receiving other EPI vaccinations, in particular 272 
pneumococcal vaccine that was introduced 10 months before RV1. Moreover such children 273 
had greater association with other socio-demographic risk factors for mortality (Appendix 274 
Table 2·5). Children from households with fewer assets had increased mortality hazard (Table 275 
1 and Web Extra Tables  2.1-2.5). We have previously published data from Site 2 showing that 276 
vulnerable infants are at greater risk of both vaccine non-receipt and of death. 29 277 
  278 
Our study has several limitations. First, vaccination population-impact evaluations are subject 279 
to temporal and secular biases, particularly for aetiologically non-specific endpoints. On the 280 
other hand, individual VE estimates may be biased by access to vaccination or choice to 281 
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vaccinate. We thus sought to determine both impact and effectiveness, and took account of 282 
socio-demographic confounding. However, successful vaccines with strong impact on disease 283 
incidence challenge sufficient accumulation of cases for individual-level analysis of adequate 284 
power, because deaths become rarer events. Thus although the impact and effectiveness point 285 
estimates were similar, impact was such that effectiveness had wide confidence bounds. 286 
Second, although we inflated our sample size to account for anticipated loss to follow-up, it is 287 
possible that migrating children differed systematically from the rest of the population, thereby 288 
biasing vaccine effectiveness estimates. Single, wealthier more educated women were more 289 
mobile, but the differences, though nominally statistically significant, were modest. The 290 
observed vaccine coverage and mortality rates in the non-migrating cohort aligned with our 291 
initial expectations. Third, retrospective updating of vaccine status may have been associated 292 
with bias toward higher apparent vaccine effectiveness.30 Coding vaccination date as date of 293 
study ascertainment rather than the date vaccination actually occurred might mitigate this bias, 294 
but this approach requires high frequency of visits. Not only is this logistically challenging in 295 
a study of this magnitude but may itself affect mortality outcome by increasing opportunity for 296 
illness recognition. Our maternal exit interviews following vaccine clinic visits showed 297 
bidirectional misclassification of about 4% (data not shown). Fourth, we went to great lengths 298 
to minimize under-ascertainment of both unvaccinated survivors and vaccinated infants who 299 
died, as previously described.19 Yet among deceased infants health passports were often buried 300 
along with the child and unavailable for review. We could not change this cultural practice 301 
despite educational campaigns by radio and through community engagement. We actively 302 
sought vaccination clinic records to obtain vaccine status of deceased children, but it was 303 
challenging to find the correct individual records of specific infants. We therefore evaluated 304 
the quality of parental reporting through quality assurance activities. Restricting analysis to 305 
deceased infants whose records were available would itself have introduced bias. Fifth, cause 306 
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of death misclassification can affect VE. Under-reporting of diarrhoea among vaccinated 307 
deceased infants will bias VE and impact estimates away from the null. However, validation 308 
studies from Africa have shown high sensitivity for diarrhoea in VA, and these are relatively 309 
robust to recall bias, parents recollect the details of their child’s final illness.31 Sixth, since date 310 
of vaccination was not always available we could not analyse vaccination status as a time-311 
varying covariate. This likely introduced a slight bias away from the null, since had we done 312 
so then the brief survival time between becoming eligible (we allowed 2 weeks for vaccination 313 
to be considered timely) and actually receiving vaccination would not have been included in 314 
vaccinated survival time. The fact that most vaccination was timely is therefore reassuring. 315 
Finally, other co-administered vaccines might also reduce diarrhoea-associated mortality thus 316 
subtly increasing apparent RV1 VE. Co-administration of other vaccines was almost universal, 317 
and we cannot account for this bias. In Site 2, where we report a combined impact of RV1 318 
introduction and a comprehensive WASH intervention, the magnitude of mortality reduction 319 
was 46%. Surveillance duration and therefore model adjustments differed across our two sites 320 
so the two results are not directly comparable. Given the unanticipated co-introduction of 321 
extensive improvements in sanitation at Site 2 our result could have been biased away from the 322 
null due to other improvements in healthcare in this region, though in scoping with stakeholders 323 
we have not become aware of any other concurrent population interventions. Notwithstanding 324 
these caveats, the implication that concurrent interventions may have synergistic benefit is 325 
intriguing and warrants further programmatic evaluation.  326 
 327 
Conclusions 328 
Childhood diarrhoea-associated mortality in this rural African population has fallen during the 329 
past decade, in part due to improvements in sanitation and treatment interventions including 330 
ORS and zinc. Our large and comprehensive study demonstrates for the first time using 331 
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empirically observed, population-based surveillance that rotavirus vaccine further reduces 332 
diarrhoea deaths in a low income, rural African population. These data add considerable weight 333 
to the WHO recommendation that countries with high childhood mortality should add rotavirus 334 
vaccine to existing public health interventions to further reduce diarrhoea deaths. 335 
  336 
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from 17th September 2012 – 1st June 2015, Site 1 463 
 464 
Figure 2:  465 
Panel A. 12-month weighted moving average smoothed trend* in all-cause and diarrhoea-466 
associated mortality in 10-51 week infants and 2-dose RV1 coverage, September 2012 to June 467 
2015, Site 1, Malawi 468 
Panel B. 12-month weighted moving average smoothed trend* in all-cause and diarrhoea-469 
associated mortality in 10-51 week infants; 2-dose RV1 coverage and 3-dose pneumococcal 470 
conjugate vaccine coverage, 2004 to 2016, Site 2, Malawi. 471 
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Figure 1: Flow diagram per STROBE guidelines of participating vaccine-eligible cohort born from 17th 481 
September 2012 – 1st June 2015, Site 1 482 
 483 
 484 
*Completion of follow-up means sufficient information was obtained by 1 year of age to determine 485 
whether the participant can be included in analysis or excluded for the reasons outlined in the 486 
figure.  487 
Excluded from analysis - death  
- Missing dates = 22  
- Migrated = 23 
- No consent = 3  
- No event = 3 
- Record error = 0 
- Household not located = 6 
Livebirths registered: 38,518 
Follow-ups initiated: 35,602 
Follow-up not completed: 173 
Follow-ups complete*: 35,429 
Excluded from analysis - survivors  
- Missing dates = 6 
- Migrated = 5,537 
- No consent = 30 
- No event = 4 
- Record error = 514  
- Household not located =196  
Excluded due to data issues:  
- ID error = 1637 
- Suspected duplicate = 119 
- Implausible birth = 31 
- Unknown issue = 181 
  
Not eligible for cohort: 
- Neonatal deaths = 844 
- Early infant deaths = 104  
29,085 included in analysis:  
Surviving = 28,718 
Deceased = 367 
Diarrhoeal deaths = 108 
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Figure 2: Panel A. 12-month weighted moving average smoothed trend* in all-cause and diarrhoea-488 
associated mortality in 10-51 week infants and 2-dose RV1 coverage, September 2012 to June 2015, Site 1. 489 
Panel B. 12-month weighted moving average smoothed trend* in all-cause and diarrhoea-associated 490 
mortality in 10-51 week infants; 2-dose RV1 coverage and 3-dose pneumococcal conjugate vaccine 491 
coverage, 2004 to 2016, Site 2. 492 
 493 
* 12-month weighted moving average smoothed trend: 494 
?̂?𝑡 =
1
24
(𝑌𝑡−6 + 𝑌𝑡+6) +
1
12
(𝑌𝑡 + 𝑌𝑡−1 + 𝑌𝑡+1 + 𝑌𝑡−2 + 𝑌𝑡+2 + 𝑌𝑡−3 + 𝑌𝑡+3 + 𝑌𝑡−4 + 𝑌𝑡+4 + 𝑌𝑡−5 + 𝑌𝑡+5) 495 
; where 𝑌𝑡 is the monthly observation at month t and ?̂?𝑡 is the locally-weighted estimate at month t.  496 
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 497 
Figure 3: Survival analysis of diarrhoea-associated death in vaccine-eligible cohort, Site 1. 498 
 499 
Panel A: Kaplan-Meier survival curve and confidence bounds, by vaccine receipt. (Deaths shown in parentheses 500 
in At-Risk table beneath the plot) 501 
Panel B: Fully parametric hazard rate over survival time, by vaccine receipt. 502 
Panel C: Vaccine effectiveness over survival time. 503 
Panel D: Hazard rate difference (between vaccinated and unvaccinated infants) over survival time. 504 
  505 
  506 
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Table 1: Vaccine-eligible cohort description and multivariable Cox proportional hazards survival analysis, Site 1. 507 
Variable 
Survived All-cause deaths Diarrhoea-deaths Cox multivariable model 
N (%) N (%) N (%) Hazard ratio‡‡ 95% CI P-value 
TOTAL 28,718 367 108    
Rotavirus vaccine 
status 
0 doses 
1 dose 
2 doses 
Missing 
1724 
563 
26086 
345 
(6%) 
(2%) 
(91%) 
(1%) 
65 
33 
266 
3 
(18%) 
(9%) 
(72%) 
(1%) 
10 
7 
91 
- 
(9%) 
(7%) 
(84%) 
1 
- 
0·66 
 
 
0·34, 1·28 
 
 
0·22 
Maternal marital 
status: 
Married 
Single 
Divorced/widow 
Died 
Missing 
25810  
1567 
1287 
20 
34 
(90%) 
(5%) 
(5%) 
(0.1%) 
(0.1%) 
283 
39 
33 
9 
3 
(77%) 
(11%) 
(9%) 
(2%) 
(1%) 
83 
11 
9 
5 
- 
(77%) 
(10%) 
(8%) 
(5%) 
1 
1·91 
1·55 
98·1 
 
1·00, 3·65 
0·74, 3·27 
39.5, 243.6 
 
0·05 
0·25 
<0·001 
Maternal education: None 
Primary 
Secondary/Tertiary 
Missing 
3173 
21963 
3543 
39 
(11%) 
(77%) 
(12%) 
(0.1%) 
46 
280 
37 
4 
(13%) 
(76%) 
(10%) 
(1%) 
13 
82 
13 
- 
(12%) 
(76%) 
(12%) 
1 
1·12 
0·95 
 
0·59, 2·11 
0·40, 2·27 
 
0·73 
0·91 
Water source 
 
Protected source 
Open source 
Missing 
23525 
5167 
26 
(82%) 
 (18%) 
 (0.1%) 
283 
81 
3 
(77%) 
 (22%) 
 (1%) 
81 
27 
- 
(75%)  
(25%) 
 
1 
1·42 
 
0·90, 2·24 
 
0·13 
Toilet facility No facility 
Some facility 
Missing 
5186 
23503 
29 
(18%) 
(82%) 
(0.1%) 
63 
301 
3 
(17%) 
(82%) 
(1%) 
20 
88 
- 
(19%) 
(81%) 
1 
1·30 
 
0·76, 2·21 
 
0·34 
House quality† Worst 
Middle 
Best 
Missing 
21922 
4302 
2464 
33 
(76%) 
(15%) 
(9%) 
(0.1%) 
297 
41 
26 
3 
(81%) 
(11%) 
(7%) 
(1%) 
86 
11 
11 
- 
(80%) 
(10%) 
(10%) 
1 
0·90 
1·71 
 
0·48, 1·72 
0·84, 3·46 
 
0·76 
0·14 
Season of birth Dry 
Rainy 
15229 
13489 
(53%) 
(47%) 
202 
165 
(55%) 
(45%) 
63 
45 
(58%) 
(42%) 
1 
0.89 
 
0.60, 1.31 
 
0.55 
 Mean (SD) Mean (SD) Mean (SD)    
Mother’s age†† 26·0 (6·6) 27·1 (7·3) 27·9 (7·9)    
Household assets‡ 1·5 (1·2) 1·2 (1·2) 1·1 (1·2) 0·72 0·59, 0·87 0·001 
† House quality is a composite of the construction materials use to make the roof, walls and floor 
†† Mother’s age is standardized to be the age at birth of the child  
‡ Household assets include: bicycle, radio, ox cart and mobile phone 
‡‡ Hazard ratio of diarrhoea-associated death 
  508 
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Table 2: Diarrhoea-associated death before and after RV1 introduction, Site 1. 509 
Time period Survived 
Diarrhoea-associated 
deaths 
Diarrhoea-associated 
mortality rate (per 1000) 
Vaccine coverage  
(% of eligible) 
Vaccination impact * 
(95% CI, P-value) 
Pre-vaccine cohort 7,690 44 5·6 N/A - 
Vaccine eligible cohort 28,718 108 3·7 91% 31% (1, 52, P=0.043) 
Jan-Jun 2012 (pre-RV1) 4,232 28 6·6 N/A - 
Jan-Jun 2013 4,339 16 3·7 89% 39% (10, 59, P=0.013) 
Jan-Jun 2014 4,180 9 2·1 94% 76% (58, 86, P<0.001) 
Jan-Jun 2015 3,830 10 2·6 95% 68% (47, 81, P<0.001) 
CI = confidence interval 
*  1 minus relative rate reduction in mortality following vaccine introduction compared to pre-introduction rate, using 
adjusted Poisson regression  
 510 
 511 
  512 
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Web Extra Materials 513 
Web Extra 1: Additional figures 514 
Web Extra Figure 1: Map of Malawi, study sites marked in red 515 
Web Extra Figure 2: Site 1 pre-vaccination cohort flow diagram per STROBE guidelines 516 
Web Extra Figure 3: Poisson model predicted diarrhoea-associated mortality vs vaccine 517 
coverage, Site 1. 518 
Web Extra 2: Sensitivity analysis using different survival cut-offs and investigating random effects 519 
Web Extra 3: Socio-demographic status, Site 1. 520 
Web Extra 4: Vaccine status construction  521 
  522 
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Web Extra 1: Additional figures 523 
 524 
Web Extra Figure 1: Map of Malawi, study sites marked in red 525 
  526 
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Web extra Figure 2: Site 1 pre-vaccination cohort flow diagram per STROBE guidelines 527 
 528 
 529 
  530 
Excluded from analysis - death  
- Missing dates = 0 
- Migrated = 5 
- No consent = 0 
- No event = 1 
- Record error = 2 
- Household not located = 0 
Livebirths registered: 10,154 
Follow-ups initiated: 9,425 
Follow-up not completed: 44 
Follow-ups complete: 9,381 
Excluded from analysis - survivors  
- Missing dates = 0 
- Migrated = 1,238 
- No consent = 10 
- No event = 3 
- Record error = 58 
- Household not located =  246 
Excluded due to data issues:  
- ID error = 506 
- Suspected duplicate = 47 
- Implausible birth = 16 
- Unknown issue = 2 
  
Not eligible for cohort: 
- Neonatal deaths = 140 
- Early infant deaths = 18 
7,818 included in analysis:  
Surviving = 7,690 
Deceased = 128 
Diarrhoeal deaths = 44 
33 
 
Web Extra Figure 3: Poisson model predicted diarrhoea-associated mortality vs vaccine coverage, Site 1. 531 
 532 
 533 
  534 
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Web Extra 2: Sensitivity survival analyses, Site 1 535 
 536 
2.1 InterVA defined diarrhoea outcome (10wk survival) 537 
Variable 
Hazard 
Ratio 
95% Confidence 
Interval 
p-value 
RV status 0 doses 
2 doses 
1·00 
0·71 
 
0·21 
 
2·35 
 
0·574 
Mother’s status Married 
Single 
Divorced/widow 
Deceased 
1·00 
2·34 
1·85 
66·60 
 
0·79 
0·54 
8·93 
 
6·93 
6·34 
469·80 
 
0·126 
0·330 
<0·001 
Mother’s education None 
Primary 
Secondary/Tertiary 
1·00 
0·57 
0·44 
 
0·23 
0·10 
 
1·42 
1·89 
 
0·230 
0·271 
Water source                  
 
Protected source 
Open source 
1·00 
1·03 
 
0·42 
 
2·53 
 
0·942 
Toilet facility None 
Some facility 
1·00 
0·94 
 
0·40 
 
2·24 
 
0·890 
House quality Worst 
Middle 
Best 
1·00 
0·88 
2·62 
 
0·26 
0·83 
 
3·00 
8·29 
 
0·842 
0·101 
Household asset index 0·69 0·48 0·99 0·041 
Global test of proportional hazards: 0·2942 
Infants eligible for inclusion in this sensitivity analysis: 27,912 survived, 31 died 
 538 
  539 
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2.2 Cohort inclusion at 6 week survival 540 
Variable 
Hazard 
Ratio 
95% Confidence 
Interval 
p-value 
RV status 0 doses 
2 doses 
1·00 
0·57 
 
0·31 
 
1·04 
 
0·066 
Mother’s status Married 
Single 
Divorced/widow 
Deceased 
1·00 
1·85 
1·45 
82·90 
 
0·97 
0·69 
33·40 
 
3·52 
3·06 
205·77 
 
0·061 
0·323 
<0·001 
Mother’s education None 
Primary 
Secondary/Tertiary 
1·00 
1·00 
0·85 
 
0·55 
0·37 
 
1·80 
1·96 
 
0·990 
0·700 
Water source                  
 
Protected source 
Open source 
1·00 
1·42 
 
0·91 
 
2·22 
 
0·122 
Toilet facility None 
Some facility 
1·00 
1·29 
 
0·77 
 
2·17 
 
0·333 
House quality Worst 
Middle 
Best 
1·00 
0·93 
1·65 
 
0·50 
0·82 
 
1·72 
3·33 
 
0·818 
0·161 
Household asset index 0·73 0·61 0·88 0·001 
Global test of proportional hazards: 0·447 
Infants eligible for inclusion in this sensitivity analysis: Survived = 28,342, died = 105 
  541 
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2.3 Cohort inclusion at 26 week survival 542 
Variable 
Hazard 
Ratio 
95% Confidence 
Interval 
p-value 
RV status 0 doses 
2 doses 
1·00 
0·72 
 
0·33 
 
1·58 
 
0·412 
Mother’s status Married 
Single 
Divorced/widow 
Deceased 
1·00 
1·69 
1·92 
136·81 
 
0·76 
0·86 
54·62 
 
3·76 
4·31 
342·69 
 
0·199 
0·111 
<0·001 
Mother’s education None 
Primary 
Secondary/Tertiary 
1·00 
1·17 
1·08 
 
0·56 
0·40 
 
2·47 
2·89 
 
0·675 
0·881 
Water source                  
 
Protected source 
Open source 
1·00 
1·42 
 
0·84 
 
2·39 
 
0·188 
Toilet facility None 
Some facility 
1·00 
1·25 
 
0·68 
 
2·30 
 
0·471 
House quality Worst 
Middle 
Best 
1·00 
0·93 
1·44 
 
0·46 
0·63 
 
1·91 
3·34 
 
0·853 
0·389 
Household asset index 0·77 0·62 0·96 0·020 
Global test of proportional hazards: 0·665 
Infants eligible for inclusion in this sensitivity analysis: Survived = 27,718, died = 77 
 543 
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2.4 Any dose of RV versus 0 doses (10 week cohort inclusion) 545 
Variable 
Hazard 
Ratio 
95% Confidence 
Interval 
p-value 
RV status 0 doses 
≥1 dose 
1·00 
0·62 
 
0·32 
 
1·20 
 
0·156 
Mother’s status Married 
Single 
Divorced/widow 
Deceased 
1·00 
1·87 
1·42 
94·73 
 
0·95 
0·65 
37·47 
 
3·68 
3·14 
239·49 
 
0·071 
0·382 
<0·001 
Mother’s education None 
Primary 
Secondary/Tertiary 
1·00 
1·43 
1·48 
 
0·70 
0·60 
 
2·89 
3·66 
 
0·324 
0. ·393 
Water source                  
 
Protected source 
Open source 
1·00 
1·56 
 
0·99 
 
2·44 
 
0·053 
Toilet facility None 
Some facility 
1·00 
1·24 
 
0·73 
 
2·12 
 
0·422 
House quality Worst 
Middle 
Best 
1·00 
0·90 
1·65 
 
0·47 
0·83 
 
1·71 
3·28 
 
0·740 
0·151 
Household asset index 0·77 0·63 0·93 0·006 
Global test of proportional hazards: 0·779 
Infants eligible for inclusion in this sensitivity analysis: Survived = 28,012, died = 101 
  546 
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2.5 All-cause non-traumatic mortality (10 week cohort inclusion) 547 
Variable 
Hazard 
Ratio 
95% Confidence 
Interval 
p-value 
RV status 0 doses 
2 doses 
1·00 
0·29 
 
0·22 
 
0·38 
 
<0·001 
Mother’s status Married 
Single 
Divorced/widow 
Deceased 
1·00 
2·27 
1·97 
49·13 
 
1·59 
1·33 
24·25 
 
3·23 
2·92 
99·56 
 
<0·001 
0·001 
<0·001 
Mother’s education None 
Primary 
Secondary/Tertiary 
1·00 
1·02 
0·75 
 
0·73 
0·45 
 
1·45 
1·24 
 
0·89 
0·26 
Water source                  
 
Protected source 
Open source 
1·00 
1·27 
 
0·98 
 
1·65 
 
0·07 
Toilet facility None 
Some facility 
1·00 
1·27 
 
0·95 
 
1·71 
 
0·11 
House quality Worst 
Middle 
Best 
1·00 
0·79 
1·15 
 
0·54 
0·74 
 
1·14 
1·79 
 
0·21 
0·53 
Household asset index 0·83 0·74 0·92 0·001 
Global test of proportional hazards: 0·0002 (ie PH assumption is rejected) 
Infants eligible for inclusion in this sensitivity analysis: Survived = 27,912, died = 317 
 548 
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Web Extra 3: Socio-demographic status, Site 1. 550 
 551 
3.1 Socio-demographic characteristics of children according to vaccination status 552 
Variable 
0 doses 1 dose 2 doses 
N (%) N (%) N (%) 
TOTAL 1,750 603 25,831 
Mother died 3 (0.2%) 0  (0%) 22 (0.1%) 
Marital status:  
Married 
Single 
Divorced/widow 
1,536 
95 
114 
(88%) 
(5%) 
(7%) 
541 
33 
28 
(90%) 
(5%) 
(5%) 
23,273 
1,406 
1,133 
(90%) 
(5%) 
(5%) 
Education: 
None 
Primary 
Secondary 
260 
1,341 
148 
(15%) 
(77%) 
(8%) 
103 
447 
52 
(17%) 
(74%) 
(9%) 
2,762 
19,771 
3,285 
(11%) 
(77%) 
(13%) 
Water source                  
Open source 
Protected source 
444 
1,304 
(25%) 
(75%) 
129 
474 
(21%) 
(79%) 
4,523 
21,308 
(18%) 
(82%) 
Toilet facility 
No facility 
Some facility 
394 
1,354 
(23%) 
(77%) 
139 
464 
(23%) 
(77%) 
4,561 
21,268 
(18%) 
(82%) 
House quality 
Worst 
Middle 
Best 
1,399 
234 
115 
(80%) 
(13%) 
(7%) 
471 
80 
52 
(78%) 
(13%) 
(9%) 
19,675 
3,906 
2,247 
(76%) 
(15%) 
(9%) 
 Mean (SD) Mean (SD) Mean (SD) 
Mother’s age 27·6 (6·76) 27·7 (7·30) 27·0 (6·58) 
Household assets 1·33 (1·15) 1·36 (1·15) 1·55 (1·18) 
 553 
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3.2 Socio-demographic characteristics of entire cohort over time 555 
 Year 
Socio-demographic factor 2012 2013 2014 2015 
Any toilet facility 78·4% 79·9% 83·4% 85·1% 
Household mobile phone ownership 38·5% 42·0% 44·6% 50·1% 
No maternal education 13·6% 11·8% 10·4% 9·4% 
Maternal primary education 74·2% 75·7% 77·3% 78·5% 
Maternal secondary / tertiary education 11·8% 12·3% 12·3% 12·1% 
 556 
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Web Extra 4: Vaccine status construction 558 
 559 
There are three sources of vaccine status information available in Malawi:  560 
- Health passports (government issued caregiver-held documents) 561 
- Caregiver recall  562 
- Under 1 government vaccine registers (filled by healthcare workers at the point of vaccination and 563 
stored in frontline health facilities) 564 
 565 
Health passports were witnessed at home-visit interviews at 4 months and 1 year of age and at verbal autopsy 566 
interviews. Degree of reliability was then assigned to vaccine data source as outlined in the table, including 567 
relative merits of each source. 568 
 569 
4.1 Vaccine data source reliability 
Data Source Strengths Weaknesses Reliability 
Health passport 
• Filled in at the point of vaccination 
• Dates included 
• Less than 5% mis-recording 
• Differential availability according to 
survival status 
High 
Under 1 register 
• Routine data, therefore should be 
available for all, irrespective of 
survival status 
• Some registers are missing or of very 
poor quality 
• Issues in tracing children through 
registers and across facilities 
• Absence of record does not mean they 
are unvaccinated 
Medium 
Caregiver recall with 
known dates 
• Dates included 
• Generally some documented evidence 
provided e.g. twins health passport 
• Uncommon High 
Caregiver recall of no 
vaccinations 
• Generally anecdotal support which 
makes it believable  
• Uncommon 
• Relies on accurate recall  
High 
Caregiver recall 
• Available for most children, regardless 
of survival status 
• Recall bias and social-desirability bias 
(in both directions), so hard to adjust for 
the uncertainty 
• Chance of interviewer bias  
Low 
 570 
The following hierarchical rules were applied to construct a binary variable indicating vaccine received or vaccine 571 
not received:  572 
1. If at home visit interview or VA a vaccine is recorded as ‘received’ in the health passport, this information 573 
will be taken as correct. 574 
2. If at home visit interview or VA a vaccine is recorded as ‘not received’ or ‘missing’, or where no health 575 
passport was seen: 576 
a. If available, the vaccine status from a health passport at any prior 4-month interview (if such 577 
occurred) will be used 578 
b. If vaccines have been recorded in the under 1 register with evidence of a date of vaccination, 579 
this vaccine status will be used 580 
c. If vaccine status is not determined by 1, 2a or 2b then caregiver report will be used. 581 
3. In case of data conflict between 4-month visit, 1 year old visit, under-1 register or maternal report, 582 
information from the health passport will be prioritised, followed by under 1 register and then caregiver 583 
report.  584 
 585 
